CJ signs license agreement with aRigen for exclusive marketing and sales of ARH-1029

Published: 2010-05-17 06:59:00

Updated: 2010-05-17 06:59:00

CJ Jeil Chedang said on May 12 that it signed a strategic alliance agreement with aRigen Pharmaceutical Inc., a drug discovery and development company focused on infectious diseases in Japan, for the exclusive marketing and sales of ARH-1029, a novel drug candidate for the treatment of peptic ulcer.

With the dual effects including both the inhibition of gastric acid and specific eradication ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.